Nature Medicine · 1 Sept 2026 · Journal Article

Obesity medicines as disruptive innovation.

Sattar

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

Lifestyle Modification and Incretin-Based Therapy for Obesity.
JAMA · 23 June 2026 · Journal Article
Read the brief in JClub
- 10 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42160059
Open in JClub
Survodutide Once Weekly for the Treatment of Adults with Obesity.
New England Journal of Medicine · 20 Aug 2026 · Randomized Controlled Trial
Once-weekly survodutide significantly reduces body weight by approximately 12-13% in adults with obesity without diabetes, outperforming placebo in a phase 3 trial.
- Open access
- 18 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42253238
Open in JClub
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ · 8 July 2026 · Systematic Review
Drugs for overweight or obesity achieve up to 14.9% weight loss at one year but vary in benefits and harms, with some also reducing cardiovascular risks.
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42419792
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read